Investors

Announcements
2012
2011
2010
2009
2008
25: Insider's dealings
24: Insider’s dealings
23: BioPorto’s patent rights strengthened for NGAL
22: BioPortos patentrettigheder for NGAL
21: Financial calendar 2009
20: Insider's dealings
19: Interim Financial Report for Q3
18: Announcement from major shareholder
17: Announcement from major shareholder
16: Shares and votes
15: Insider's dealings
14: Insider's dealings
13: Announcement from major shareholder
12: Interim Financial Report for Q2 2008
11: BioPorto’s NGAL patent approved for issue in Europe
10: BioPorto launches Rat NGAL ELISA Kit
09: New diagnostic application of the APC-PCI test
08: Articles of association
07: Interim financial statement, first quarter 2008
06: Issue of warrants in BioPorto A/S
05: Devl. of Annual General Meeting
04: Annual General Meeting
03: Annual Report 2007
02: Financial calendar
01: Name change in affiliate
2007
2006
2005
2004
Presentations
Key Figures
Financial Calendar 2012
Analyst coverage
Company Documents
News mail
Contact investor relations

13: Announcement from major shareholder

August 29 2008

Announcement no. 13

Announcement from major shareholder

BioPorto A/S has been informed that T. Bernt Nielsen A/S and its associates hold 3,215,927 shares with a nominal value of DKK 3,00 per share in BioPorto A/S, which represents 8,4% of the shares.

Further details:

Christina Tønnesen, Investor Relations

Tel: +45 4529 0000

E-mail: investor@bioporto.com

Downloads

meddelelse 13 2008.pdf (0 B)

announcement 13 2008.pdf (0 B)